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INTRODUCTION 
Normal fetal development requires the coordination of specific 
events at precise times during gestation. The coordination of these 
events occurs as a result of communication between mother and fetus via 
hormones and other paracrine factors. Hormones are intercellular 
communicators that are synthesized in a specific tissue, secreted into 
the bloodstream, and received by a different tissue. The receipt of the 
hormone signal by a specific receptor initiates a process that eventually 
results in some metabolic change in the receiving tissue. 
Prolactin is a pituitary hormone secreted during gestation with 
several functions. The major role of prolactin in gestation appears to 
be as a lactogenic stimulus in mammary gland tissues (1). There are 
several prolactin-like hormones synthesized in the placenta of the 
developing fetus and secreted into the maternal blood. These include the 
placental lactogens (2-8), the prolactin-like proteins A and B (9-13), 
and mitogen regulated protein (MRP) (14) also called proliferin (PLF) 
(15,16). All of these secreted glycoproteins are similar in their core 
polypeptide molecular weight and their homology to prolactin. Further­
more, the placental lactogens have lactogenic activity (17) and have been 
implicated in mammary gland preparation for lactation and fetal growth 
(18). One current hypothesis explains that placental hormone expression 
marks a shift in the control of pregnancy from the pituitary to the 
placenta and, in the case of placental lactogens, allows more precise 
developmental regulation of prolactin-like hormones (18-21). The 
2 
placental lactogens have been characterized in much greater detail than 
either prolactin-like proteins A and B or MRP with respect to possible 
functions in fetal development and the maternal response to fetal 
development. The Nilsen-Hamilton research group is currently studying 
MRP in an effort to fully characterize this secreted glycoprotein and 
define its function during murine gestation. 
MRP represents a family of glycoproteins of 34 kDa average molecular 
weight originally discovered as a secretion product of growth factor 
stimulated mouse embryo 3T3 cells (22). MRP is identical to PLF (23), 
described by Linzer and Nathans in Balb/c 3T3 cells and expressed in the 
mouse placenta (15). MRP has 32 percent homology to mouse prolactin 
according to sequence analysis of the cDNA (24) and has a polypeptide 
molecular weight of about 22 kDa. MRP exhibits a distinct temporal 
profile of synthesis and secretion during murine gestation with peak 
levels occurring in the placenta and maternal serum at mid-gestation with 
a subsequent rapid decline at late gestation (16,25,26). The appearance 
in the blood at mid-gestation, its synthesis in the placenta, and its 
homology to prolactin indicates that MRP is, like the placental lacto­
gens, a hormone involved in fetal development. 
If MRP is a placental hormone, it should bind to its target tissue 
via a receptor. Lee and Nathans (27) showed that recombinant PLF binds 
to the cation-independent mannose-6-phosphate receptor in murine liver 
and placental membrane preparations during late gestation. Approximately 
80-90 percent of the cation-independent mannose-6-phosphate receptors are 
located intracellularly (28) and participate in translocating proteins to 
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the lysosoraes (29,30). The other 10-20 percent are located on the cell 
surface. The mannose-6-phosphate residue recognized by the receptor is a 
high mannose type that is N-linked through asparagine to the polypeptide 
backbone (31,32). The phosphate is transferred to the mannose by the 
addition of N-acetylglucosaminyl 1-phosphate followed by hydrolysis of 
the N-acetylglucosaraine (33). Cation-independent mannose-6-phosphate 
receptors are present in the Golgi (30). When cells are incubated with 
antibodies to the mannose-6-phosphate receptor, the efficiency of 
lysosomal targeting is decreased (29) and it is thought that ligand 
binding occurs in the trans Golgi (34). The receptor is a 300 kDa 
glycoprotein (34) and there is evidence that it is the same receptor as 
the insulin-like growth factor II (IGF-II) receptor (35-37). This is 
interesting with respect to the cell surface mannose-6-phosphate receptor 
because it indicates the receptor could mediate growth factor stimulated 
events. IGF-II is not glycosylated, however, and this indicates that the 
mannose-6-phosphate receptor must have separate binding sites for IGF-II 
and mannose-6-phosphorylated glycoproteins because the presence of 
mannose-6-phosphate is absolutely required for lysosomal targeting (38). 
MRP binding to the mannose-6-phosphate receptor could be a mechanism 
used intracellularly to direct MRP to the lysosomes or to mediate a 
functional response to MRP bound to receptor at the cell surface. Recent 
evidence shows that MRP binding to the cation-independent mannose-6-
phosphate receptor on canine kidney basolateral membranes activates 
phospholipase C (38). Furthermore, anti-mannose-6-phosphate receptor 
abolished this activation. This could reflect a signal transduction 
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mechanism of the bound MRP at the cell surface. However, results from 
this laboratory show that MRP circulating in the maternal bloodstream 
does not contain mannose-6-phosphate. Thus, any signal transduction 
events attributed to the MRP-mannose-6-phosphate receptor interaction at 
the cell surface cannot occur in vivo on a tissue other than the pla­
centa. 
To characterize a specific receptor for MRP, several criteria must 
be established (39). One very important factor in this characterization 
is that the receptor must be saturable to ensure a specific interaction 
between ligand and receptor. A receptor is further characterized by its 
dissociation constant, K^, and maximal binding, according to 
analysis by a Scatchard plot (40). The allows an assessment of the 
affinity of the ligand for the receptor and allows an assessment of 
the size of the receptor population. Furthermore, the obtained by the 
above steady-state method should be consistent with the obtained from 
kinetic studies. The shape of the Scatchard plot will also help to 
determine whether there are receptor populations with different affini­
ties for the ligand. A plot resulting in a straight line indicates a 
single affinity receptor. The kinetic studies involve determining 
association and dissociation rate constants. One defines an association 
rate constant, k^, by conducting receptor binding over a number of 
consecutive time points. The measurement of k^ is completed by solving 
the second order rate equation at each time point in the linear range of 
the association time course and calculating an average k^. The dissocia­
tion rate constant, k ^ , is determined by following the time course of 
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dissociation of the receptor-ligand complex. A logarithmic transforma­
tion of the resultant data allows the calculation of k ^ by measuring the 
slope of the line of this transformation. A straight line shows a first-
order reaction and presumably a reaction involving a receptor with a 
single affinity. The value of k should be consistent with the 
obtained from a Scatchard analysis. The final criterion used to es­
tablish the existence of a receptor is its specificity. One must test 
the receptor preparation for binding to its presumed ligand in the 
presence of competing ligands to insure a specific ligand-receptor 
interaction. 
My dissertation research hypothesis is that MRP is a new placental 
hormone involved in fetal development that exerts its functional effects 
via a specific receptor on a tissue separate from placenta. I tested 
this hypothesis by identifying and characterizing a tissue receptor that 
specifically binds MRP. 
Explanation of Thesis/Dissertation Format 
I am using the alternate format for this dissertation as outlined in 
the Iowa State University Graduate College Thesis Manual. The introduc­
tion provides a background into the research and describes the research 
motivation. The first section entitled, "Mitogen regulated protein (MRP; 
Proliferin) blood clearance and tissue uptake during murine gestation" 
describes the different blood clearance profiles of tracer radioiodinated 
MRP at multiple stages of murine gestation and provides evidence of 
uterine and mammary gland tissue uptake and utilization at mid-gestation. 
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I conducted all the experimental studies involving in vivo clearance of 
radioiodinated MRP, tissue uptake and utilization of radioiodinated MRP, 
tissue utilization of radioiodinated MRP after chloroquine treatment of 
pregnant mice, radioiodination of MRP, and mannose-6-phosphate receptor 
affinity column chromatography of radioiodinated MRP. Yu Fang conducted 
the experimental studies concerning the quantitation of MRP in maternal 
plasma and Adnan Mubaidin contributed the experimental data concerning 
the mannose-6-phosphate content of placental and plasma MRP. I also per­
formed the literature review and prepared the manuscript. I performed 
the research outlined in the first section to determine the most appro­
priate period of gestation to investigate the existence of a proposed MRP 
receptor and to identify a tissue most likely to contain the MRP recep­
tor. In the second section entitled, "Characterization of the mitogen-
règulated protein (MRP; Proliferin) receptor from uterine membranes," I 
conducted all of the experimental studies, performed the literature 
review, and prepared the manuscript. The summary describes my disserta­
tion conclusions and describes ideas for future research. The references 
following the summary are a list of the references used in the introduc­
tion and summary. The references following sections one and two are 
listed in accordance with the format of the journal in which the papers 
will be submitted. The references following the summary are listed in 
accordance with the format of the approved style manual for the Depart­
ment of Biochemistry and Biophysics as recommended in the Iowa State 
University Graduate College Thesis Manual. 
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SECTION I. MITOGEN REGULATED PROTEIN 
(MRP; PROLIFERIN) BLOOD CLEARANCE AND 
TISSUE UPTAKE DURING MURINE GESTATION 
8 
Mitogen Regulated Protein (MRP; Proliferin) Blood Clearance and 
Tissue Uptake During Murine Gestation 
11 2 Joseph T. Nelson , Yu Fang , Adnan Mubaidin, Christopher Gabel , 
2 1 Richard Einstein , and Marit Nilsen-Hamilton 
Department of Biochemistry and Biophysics, 
Iowa State University, Ames, Iowa 50011 
and 
Department of Anatomy and Cell Biology, 
College of Physicians and Surgeons of Columbia University, 
630 W. 168th Street, New York, NY 10032 
9 
ABSTRACT 
Mitogen regulated protein (MRP; also called proliferin) is a 34 IcDa 
glycoprotein secreted during murine gestation. Its temporal profile of 
synthesis and secretion and its homology to prolactin indicate an 
hormonal role in fetal development. To identify its target tissues in 
125 
vivo, we injected tracer amounts of I-labeled MRP into nonpregnant 
mice and mice at various days of gestation. At mid-gestation the 
clearance profile was biphasic and provided evidence for two half-lives 
for MRP of 0.6 hour and about 8 hours. Both half-lives of MRP were 
significantly shorter than the half-life of 10 hours measured for serum 
albumin. Our data show that mammary gland and uterus take up and degrade 
MRP whereas MRP is taken up but not degraded by liver, heart, spleen, and 
kidney. MRP degradation in the mammary gland and uterus is reduced by 
prior treatment with chloroquine which inhibits lysosomal-mediated 
degradation. We propose that MRP is cleared from the blood by receptor-
mediated endocytosis with subsequent degradation by mammary gland and 
uterus. Because degradation by their target cells is a fate of many 
hormones and growth factors, we suggest that mammary gland and uterus are 
also target tissues for MRP action. 
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INTRODUCTION 
Mitogen Regulated Protein (MRP) is a 34 kDa glycoprotein first 
identified as a protein secreted by growth factor-stimulated mouse embryo 
3T3 cells (1). MRP is identical to proliferin (PLF), a prolactin-
related protein found in murine placenta during gestation (2). The 
temporal profile of MRP synthesis in trophoblastic giant cells, its 
appearance in maternal blood during a well-defined gestational period, 
and its similarity to prolactin indicate that MRP might be a placental 
hormone involved in fetal development (3-6). MRP produced from a 
recombinant plasmid by transformed Chinese Hamster Ovary (CHO) cells 
binds to the cation-independent mannose-6-phosphate receptor in maternal 
and fetal liver and in placental membranes (7). Although this interac­
tion with the mannose-6-phosphate receptor can initiate signal transduc­
tion (8), our results suggest that this is not the means by which MRP 
acts in vivo because we show that MRP in the maternal blood does not 
possess mannose-6-phosphate. 
Here, we report the in vivo clearance of radiolabelled MRP at 
different stages of gestation and compare this with the clearance of 
serum albumin. Our results show that tracer MRP is cleared from the 
blood more rapidly than serum albumin in nonpregnant mice. The mammary 
gland and uterus also specifically degrade MRP. This degradation may be 
due to the presence of a specific receptor for MRP in these tissues that 
il 
is involved in its clearance. Furthermore, the specific degradation of 
MRP in the mammary gland and uterus may be a consequence of these tissues 
being targets for this newly-discovered placental hormone-like protein. 
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MATERIALS AND METHODS 
Materials 
MRP was purified in our laboratory from conditioned medium of a 
Swiss 3T3 cell line stimulated by fibroblast growth factor (FGF) and 
phorbol myristate acetate in the presence of 10 mM ammonium chloride. 
All chemicals used were reagent grade or more pure. Bovine serum albumin 
125 (BSA) was purchased from Sigma Chemical Company. Na I was purchased 
125 from Amersham, enzymobeads from Bio-Rad, I-protein A from ICN, and 
pansorbin from Calbiochem. Rabbit anti-MRP was prepared in our labora­
tory using purified MRP from conditioned medium of Swiss 3T3 cells (9). 
All other chemical were purchased from Fisher Scientific or Sigma 
Chemical Company. 
Methods 
Radioiodination 
MRP and BSA were radioiodinated using immobilized glucose oxidase 
and lactoperoxidase (Enzymobeads, BioRad Company). We used the lacto-
peroxidase labeling method because the requisite enzymes catalyze fewer 
side reactions than in other labeling methods and the protein is more 
likely to retain biological activity (10). Three to six micrograms per 
milliliter of MRP or 130 /ig/ml of BSA was incubated with 50 pi of washed 
125 Enzymobeads, 6.5 mCi/ml of Na I, and 323 pg/ml of a-D-glucose in 65 mM 
sodium phosphate buffer, pH 7.2 for 25 minutes at 22°C in a total volume 
of 155 111. Fifty millimolar sodium phosphate buffer, pH 7.4 was added to 
the reaction mixture to a final volume of one milliliter. The mixture 
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was raicrofuged for five minutes at 4°C. The supernatant was loaded onto 
a 10 DG column (BioRad) previously washed with one percent BSA in 50 mM 
sodium phosphate buffer, pH 7.4 and eluted with 50 mM sodium phosphate 
buffer, pH 7.4. One milliliter fractions to which 100 /il of one percent 
BSA was previously added were collected. Fractions 4, 5, and 6 were 
pooled, loaded onto a second 10 DG column, and 1 ml fractions collected. 
Each fraction was analyzed by trichloroacetic acid (TCA) precipitation 
and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Fractions containing greater than 75 percent TCA precipitable 
protein were used for experiments. The amount of TCA precipitable 
protein declined in radioiodinated MRP preparations with storage at 4°C. 
Therefore, we often passed stored radioiodinated MRP through a desalting 
column prior to use for in vivo clearance studies. The reason for the 
rapid decline in TCA precipitable cpm is believed to be adsorption to the 
walls of the vessel. We found the decline could be prevented by includ­
ing one percent BSA or 140 mM NaCl in the MRP stock solution. Radio­
iodinated BSA was quite stable with storage at 4°C. 
SDS Dolvacrvlamide gel electrophoresis fSDS-PAGE) 
SDS-PAGE was performed according to Nilsen-Hamilton and Hamilton 
(11). The resolving gel consisted of a 7.5-15 percent linear polyacryl­
amide gradient and the stacking gel was five percent polyacrylamide. 
Electrophoresis was completed at 12.5 mAmps for 4.5-5 hours at 22°C. 
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Trichloroacetic acid (TCA) precipitation 
Two methods of acid precipitation were used. Ascending thin layer 
chromatography was used to separate labeled protein from free label when 
it was possible to use small volumes of radiolabeled protein. Silica 
gel-impregnated glass fiber strips (4.8 cm x 1 cm) were spotted 1 cm from 
the bottom with an equal volume of two percent potassium iodide and 
radiolabeled protein and developed in 30 percent (v/v) methanol, 10 
percent (v/v) glacial acetic acid and 10 percent (v/v) trichloracetic 
acid, and dried at room temperature. The developed strips were cut in 
half to separate the acid soluble and insoluble material. Each half was 
counted in a Tracor Analytic Gamma Trac 1191 gamma counter. To obtain 
the fraction of the TCA precipitable protein, the counts remaining at the 
origin were divided by the total counts spotted. 
The second method of precipitation, which involved filtering the 
sample through borosilicate microfiber filters, was used for large sample 
volumes. Potassium iodide was added to each radiolabeled sample to one 
percent (v/v) and the samples were incubated at 4°C in 10 percent TCA for 
30 minutes. To determine the total cpm, each sample was counted in a 
gamma counter before filtering. The solution was filtered under vacuum, 
the filter was washed four times with 10 percent TCA and counted in a 
gamma counter. To obtain the fraction of TCA precipitable cpm, the cpm 
remaining on the filter were divided by the total cpm in the 
radiolabelled sample. 
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Radioimmunoassay (RIA) 
To each duplicate 50 nl sample or standard containing MRP, anti-MRP 
was added to a final dilution of 1/5000 and incubated in 10 mM sodium 
phosphate, 150 mM sodium chloride, 10 mM EDTA, and one percent BSA at pH 
7.5 for 6 hours at 4°C in a total volume of 230 /xl. Radiolabelled MRP 
was added to 5-7 pg/ml (60,000-80,000 cpm/ml)to a total volume of 250 nl 
and incubated for 12 hours at 4°C. Pansorbin was added to one percent 
(v/v) and allowed to stand for one hour at 22°C. The mixture was spun in 
a microfuge at 4°C for 10 min, the supernatants aspirated, and the 
pellets counted in a gamma counter. Nonspecific binding was calculated 
to be the amount of label in the pellet in the presence of 1,000 ng/ml of 
unlabeled MRP and was subtracted from all samples to obtain specific 
binding. The linear range of the assay was 0.2-20 ng MRP. 
Western blot 
After resolution by SDS-PAGE, the gel containing the MRP was soaked 
in 25 mM Tris, 192 mM glycine, 20 percent methanol, pH 8.0 for 30 minutes 
at 22°C. The proteins were transferred to a nitrocellulose membrane with 
a Hoefer TE 50 apparatus at 90 V for four hours at 22°C. The membrane 
was stained with Ponceau S to verify that proteins were transferred. 
After destaining, the membrane was incubated for 12 hours at 4°C in a, 
solution containing five percent (w/v) nonfat milk, 140 mM sodium 
chloride, 5 mM potassium chloride, 0.4 mM dibasic sodium phosphate, 25 mM 
Tris, pH 7.4 containing 0.02 percent (w/v) sodium azide. The solution 
was poured off and a fresh five percent nonfat milk solution containing 
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anti-MRP to a final dilution of 1/200 was added and the membrane was 
incubated for 90 min at 22°C. This solution was poured off and the 
membrane was washed for 10 minutes at 22°C with buffer I (140 mM sodium 
chloride, 5 mM potassium chloride, 0.4 mM sodium phosphate, 25 mM Tris, 
pH 7.4). This was followed by a second wash for 10 min in buffer I 
containing 0.05 percent (v/v) NP-40 and a final 10 min wash in buffer I. 
5 125 A solution of 3.6*10 cpm/ml of I-protein A in five percent nonfat 
milk in buffer I was added to the membrane for 30 minutes at 22°C. The 
125 protein A solution was then poured off and the membrane was washed 
three times with buffer I as just described. The membrane was dried and 
the radioactivity detected by autoradiography. 
Mannose-6-phosphate receptor column chromatopraphv 
Purified MRP and MRP in samples of plasma and placental extract were 
analyzed for their content of mannose-6-phosphate by their ability to 
bind to the mannose-6-phosphate receptor. The samples were applied to a 
mannose-6-phosphate receptor affinity column as described (12). The 
column was washed with 15 ml of column buffer (50 mM sodium phosphate, 
150 mM sodium chloride, 5 mM ^^glycerophosphate, 2 mM EDTA, and 1 mM 
PMSF) and 1 ml fractions were collected. Fifteen milliters of column 
buffer containing 5 mM mannose-6-phosphate was then added to elute the 
mannose-6-phosphate-containing compounds and 1 ml fractions collected. 
For studies in which unlabeled MRP was passed through the column for 
131 later analysis by radioimmunoassay, a standard mixture of I-ligands 
containing mannose-6-phosphate were mixed with the samples prior to 
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resolution through the column. The mannose-6-phosphate-containing 
ligands were obtained from secretions of J774 macrophage cells (12). 
When radioiodinated MRP was analyzed for mannose-6-phosphate content, a 
125 
mixture of I-ligands were resolved separately through the column. The 
amount of MRP in each fraction from the column was determined by radio­
immunoassay for unlabeled samples of MRP or by TCA precipitation fol-
125 lowed by scintillation spectroscopy for I-labeled MRP. The percentage 
of the MRP containing mannose-6-phosphate was determined by dividing the 
total MRP in the bound fractions by the total MRP that passed through the 
column. 
Placental extract preparation 
Placentae were dissected from CF-1 outbred mice, weighed, and 
immediately frozen by immersion in liquid nitrogen. The frozen tissue 
was stored at -70°C until ready for use. The frozen tissue was pulver­
ized with mortar and pestle and homogenized at 9 ml/g tissue in homogen­
izing buffer (10 mM sodium phosphate, 150 mM sodium chloride, 0.2 mM 
magnesium sulfate, 1 mM EDTA, pH 7.5) using a Tekmar Tissuemizer at 4°C. 
The homogenate was spun at 13,000 g for 10 min at 4°C, the supernatant 
was aspirated and adjusted to 10 mM EDTA, and stored at -70°C until 
needed. 
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In vivo I-MRP clearance 
Outbred CF-1 female mice were anaesthetized with ether and 100-360 
ng/ml radiolabelled MRP (10-20 fiCi/fig) or 6.7 /ig/ml BSA (2.3 fiCi/ng) was 
injected directly into the heart. Blood and tissue samples were 
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collected at several time intervals after injection. For the zero-time 
point, blood was collected at 2-4 minutes after injection. Blood was 
collected from the orbital sinus. Immediately after collection, each 
sample was put on ice and counted for gamma emission. Tissue samples 
were weighed and homogenized using the Tekmar Tissuemizer at high setting 
for 20-40 seconds. All samples were analyzed for TCA precipitable 
protein. Clearance rates were assumed to be first order and calculated 
from the slopes of semi-logarithmic plots of the log % dose vs. time 
using the method of least squares where log % dose = log [(sample TCA 
precpitable cpm/TCA precpitable cpm injected/ml blood)*100]. Half-lives 
were calculated using the equation, l/(2.303*clearance rate). 
For mice treated with chloroquine diphosphate, mice were injected 
intraperitoneally with chloroquine in sterile water at a dose of 60 ug/gm 
mouse weight. Injections were given daily from day 6 through 11 days of 
125 
gestation. At 11 days of gestation, the mice were injected with I-
MRP and sacrificed after two hours for analysis of the distribution of 
MRP in the tissues. Mice receiving daily injections of sterile water 
were used as controls. 
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RESULTS 
Plasma and Placental MRP Concentrations 
During Gestation 
To understand the relative contribution of the placenta and maternal 
tissues to the level of MRP in the blood, we compared the plasma profile 
of MRP with the profile of MRP mRNA in the placenta. The plasma con­
centrations of MRP peaks on day 10 of gestation and falls at a rate of 20 
percent per day through day 15 (Figure la). By day 17, only three per­
cent of the peak levels of MRP remain in the blood. This temporal pro­
file of MRP blood concentration is qualitatively in agreement with Lee et 
al. (3) as measured by radioimmunoassay, although they did not estimate 
the rate of decline of MRP after its peak. The decline in MRP levels is 
first order and can be represented by a half-life of 33 hours (Figure 
lb). As well, using data published elsewhere (4), we have estimated that 
the rate of decline of MRP mRNA in the placenta as a function of gesta­
tion can also be represented by a first order decay curve with a calcu­
lated half-life of 48 hours. 
Mannose-5-Phosphate Receptor Binding 
Lee and Nathans (7) found that recombinant MRP expressed in CHO 
cells bound to the cation-independent mannose-6-phosphate receptor. We 
tested MRP obtained from maternal plasma and placental extracts, as well 
as radioiodinated MRP, for binding to the mannose-6-phosphate receptor 
(Table 1). Plasma samples from day 9 through day 17 of gestation did not 
bind but most of the placental MRP from day 13 pregnant mice bound the 
Figure 1. Gestational profile of MRP concentrations in the maternal 
circulation, a) The relative amount of MRP in 2 /il plasma 
samples were measured by a densitometric scan of a Western 
blot. Each point represents the average and standard devia­
tion of blood plasma obtained from two mice (days 9-16) or one 
mouse (day 17, 18). b) semi-logarithmic plot of decline of 
(•) MRP in plasma and (A) mRNA starting at day 10 of gesta­
tion. The clearance rate was determined from the slope of the 
plot and half-life calculated using equation, 
693/2.3*slope. Slope/correlation coefficient: 
-0.009/-0.974 and hours (MRP) and -0.006/ -0.981 and 
t^y2=48 hours (m-RNA). 
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Table 1. Mannose-6-phosphate content of MRP 
Source of MRP % bound 
Plasma - gestation day 9-17^ 0 
Placenta - gestation day 13 88 
Swiss 3T3 cells 38 
Radioiodinated from Swiss 3T3 cells 43 
Radioiodinated and mouse plasma at 37°C for 10 rain 12 
NOTE• Samples to be loaded on the mannose-6-phosphate receptor column 
were prepared as described in Materials and Methods. For un­
labeled samples from plasma, placenta, and Swiss 3T3 cells, the 
percentage of MRP bound to the mannose-6-phosphate receptor was 
measured by RIA. For radioiodinated MRP, the samples were loaded 
onto the column and the percentage of the TCA precipitable label 
that bound to the mannose-6-phosphate receptor was calculated 
based on the total TCA precipitable label recovered in the flow 
through and mannose-6-phosphate eluted fractions. 
^Plasma samples from days 9, 11, 14, 15, 16, and 17 were separately 
analyzed. 
mannose-6-phosphate receptor. Incubating radioiodinated MRP for 10 
minutes in mouse plasma reduced binding to the mannose-6-phosphate 
receptor from 43 percent to 12 percent bound. 
Comparison of MRP and BSA Clearance In Vivo 
The clearance profiles of MRP and BSA were measured after injecting 
tracer amounts of each radioiodinated protein into nonpregnant mice 
(Figure 2a). Homogeneous radioiodinated protein preparations were 
Figure 2. Clearance profiles of BSA and MRP in nonpregnant mice, a) 
125 125 Nonpregnant mice were injected with a) I-BSA (•) or I-
MRP (A) directly into the heart and blood was collected at 
times after injection. % dose = (TCA precipitable cpm in 
sample/TCA precipitable cpm injected/ml serum)*100. Clearance 
rates and correlation coefficients were calculated as de­
scribed in Materials and Methods. The calculated clearance 
rates/correlation coefficients were; MRP: -0.0625 hour/ 
-0.974 (between 1.5 and 16 hours); BSA: -0.0296/-0.983. The 
value at each point is the average of the results obtained 
from two mice for BSA and two to six mice for MRP. b) 
Radioiodinated MRP (M) and BSA (B). 
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used in these studies (Figure 2b). Because it is heterogeneously 
glycosylated, radioiodinated MRP migrates on an SDS-PAGE as a broad, 
diffuse band (1). 
Radioiodinated serum albumin exhibited a monophasic blood clearance 
profile while radioiodinated MRP exhibited an initial accumulation in the 
blood followed by a monophasic clearance profile between 1.5 and 16 hours 
-1 
after injection. Clearance rates were calculated to be 0.0625 hour and 
0.0296 hour ^ for MRP and BSA, respectively. The calculated half lives 
of MRP and BSA were 4.8 and 10.2 hours, respectively. The clearance 
profiles of MRP at 6 and 15 days of gestation were very similar to that 
of nonpregnant mice. 
MRP Clearance at Mid-gestation 
Clearance of MRP on day 11 was biphasic and did not include an 
initial period of slow release into the blood. Figure 3a shows the 
initial fast clearance profile of MRP after injecting tracer radio­
iodinated MRP into mice at 11 days of gestation. This fast rate was 
observed between 0 and 90 minutes after injection. A slower clearance 
rate was observed between 90 minutes and 16 hours after injection (Figure 
3b). This biphasic profile was only observed with mice at 11 days of 
gestation. At other times of gestation the initial 90 min period was 
125 
marked by a slow rise in the plasma MRP level. A comparison of the 
calculated clearance rates, correlation coefficients, and half-lives of 
MRP at different stages of gestation is given in Table 2. 
Figure 3. Clearance profiles of MRP at 11 days of gestation showing fast 
and slow clearance. Mice at 11 days of gestation were 
125 injected with I-MRP directly into the heart and blood was 
collected at times after injection. % dose = (TCA 
precipitable cpm in sample/TCA precpitable cpm injected/ml 
blood)*100. The results for the first 2 hours (a) are plotted 
separately from the results for the 0-16 hour period (b). 
Clearance rates and correlation coefficients were calculated 
as described in Materials and Methods. The calculated 
clearance rates/correlation coefficients were; initial fast 
-1 
rate (0-90 minutes) = -0.467 hour /0.979; slow rate (1.5-16 
hour) = -0.0371/-0.948. Values at each point are the average 
of blood samples from eight mice at t=0-60 minutes and at 
least two mice at t=1.5-16 hours. A nontransformed, O 
logarithmically transformed. 
TIME (hours) 
0.00 4.25 8.50 12.75 17.00 
TIME (hours) 
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clearance at different stages of gestation Table 2. I-MRP 
Clearance Correlation Half-life 
Day of gestation Rate Coefficient (hours) 
(% dose decline/hr) 
nonpregnant -0.0625 -0.974 4.8 
5 day -0.0637 -0.999 4.7 
11 day 
fast -0.467 -0.979 0.6 
slow -0.0371 -0.948 8.1 
15 day -0.0709 -0.987 4.2 
NOTE• Radioiodinated MRP was injected into the heart of nonpregnant, 6, 
11, and 15 day pregnant mice. Serum samples (50-100 /il) were 
collected at various times after injection and the percentage of 
TCA precipitable protein was determined. The % dose was cal­
culated at each sample time by the equation; % dose = (TCA 
precipitable cpm in sample/TCA precipitable cpm injected/ml 
blood)*100. The clearance rate and half-lives were calculated as 
described in Materials and Methods. For all but day 11 of 
125 pregnancy, there was a slow increase in I-MRP blood levels over 
125 the first two hours after injection of I-MRP. MRP clearance 
rates were calculated using time points following the initial 
increase in blood MRP content. 
MRP Stability in Blood 
To determine if the rapid clearance of MRP at day 11 of gestation is 
due to MRP degradation in the blood and subsequent clearance of a 
125 
radiolabelled breakdown product, we incubated I-MRP with serum 
obtained from nonpregnant and 11-day pregnant mice at 37°C. The samples 
were then resolved by SDS-PAGE. There were no detectable breakdown 
29 
products in serum from nonpregnant or 11-day pregnant mice over a 
two-hour incubation period as analyzed by autoradiography after SDS-
125 
PAGE. In addition, there was no change in the intensity of I-MRP 
after incubation with serum at 37°C for up to two hours when compared 
125 
with the intensity of I-MRP at 0 time as measured by densitometric 
scanning of the autoradiogram. There was no change in the percentage of 
TCA precipitable protein over the same two hour incubation period. 
MRP and BSA Uptake by Tissues 
125 We surveyed tissues for uptake of radiolabel after injection of I 
labeled serum albumin and MRP. Table 3 shows the tissue accumulation, 
tissue/blood ratio, and the percentage of TCA precipitable protein in 
each tissue four hours after injection. Similar results were found from 
two to 16 hours after injection. With the exception of mammary gland and 
uterus, there was no significant difference in radiolabel associated with 
the tissues surveyed. For all tissues, the tissue/blood ratio for MRP 
was higher than for BSA. There was also a much lower percentage of TCA 
precipitable radiolabel in mammary gland and uterus for the MRP-injected 
mice than for MRP in other tissues and for BSA in these tissues. 
We examined the tissue uptake of radioiodinated MRP at 11 days of 
gestation (Figure 4). Maximal MRP content is achieved within one to two 
hours of its injection for all tissues. There is a general trend toward 
decreasing amounts in all tissues after reaching its peak with time after 
injection with the exception of the spleen. There was significantly 
(p<.01) higher tissue associated radiolabel in the liver and uterus one 
30 
Table 3. Comparison of tissue associated radiolabel four hours after 
125 injection of -I-protein into nonpregnant mice 
% of total dose % TCA precipitable 
injected/g tissue tissue/blood protein 
BSA MRP BSA MRP BSA MRP 
(n=2) (n=4) 
liver 2 .6±0 .8 2 .6±0 .4 0 .27 1 .46 71±4 56+4 
heart 5 .1+2 .5 3 .5±1, .2 0, .53 1 .96 77+0 66±18 
spleen 1 .1+0 .1 1 .5±G, .6 0, .12 0 .81 52 49±17 
kidney 4, ,7+1, ,5 3, 3+2. 7 0. ,49 1, ,84 83±22 46+29 
mammary 
gland 2. 0±1. 5 0. 8±0. 3 0. 21 0. 46 42+8 10+10 
uterus 2. 9±1. 5 1. 4±0. 4 0. 31 0. 77 92±22 18+11 
NOTE. Radioiodinated protein was injected into the heart of nonpregnant 
mice and the mice were sacrificed four hours later. Tissues were 
dissected, counted for gamma emission, and TCA precipitation 
performed as described in Materials and Methods. The tissue/blood 
ratio is the percent of the total dose of the tissue divided by 
the percent of the total dose in the blood at four hours. The 
percentage of TCA precipitable protein is the TCA precipitable cpm 
associated with the tissue divided by the total cpm associated 
with the tissue. 
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Figure 4. Tissue distribution of MRP. Total tissue-associated I-MRP 
in 11 day mice for kidney (K), spleen (S), liver (L), mammary 
gland (MG), and uterus (U) at 30 minutes and 1, 2 and 4 hours 
after injection. % dose = (tissue associated cpm/total cpm 
injected/g tissue)*100. Values are the average and standard 
deviation of three to eight mice at each time. Bars: open, 
30 minutes; close hatches, 1 hour; wide hatches, 2 hours; 
stippled, 4 hours. 
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hour after injection in 11 day pregnant mice when compared with nonpreg­
nant mice. 
125 The tissue-blood ratios of I-MRP were surveyed in nonpregnant 
mice and mice at 11 days of gestation (Figure 5). The ratios were 
consistently higher in 11 day pregnant mice than the same ratios in 
nonpregnant mice. Another major difference between nonpregnant and 11 
day pregnant mice was the rate of increase in tissue/blood ratios of MRP 
in 11 day pregnant mice with time after injection. The increase in the 
tissue/blood ratio between 30 and 60 minutes after injection was 19-fold 
in uterus, 10-fold in mammary gland, and 9-fold in liver of 11 day 
pregnant mice. For nonpregnant mice, the increase in tissue/blood ratio 
over the same time period was 1.6-, 1.4-, and 1.9-fold in uterus, mammary 
gland, and liver, respectively. The highest tissue/blood ratios at 11 
125 days of gestation occurred at two hours after injection of I-MRP for 
all tissues except heart. 
MRP Degradation in Tissues at 
11 Days of Gestation 
We examined the percentage of TCA precipitable radiolabel in tissues 
at 11 days of gestation (Figure 6). With time after injection, the 
125 percent of TCA precipitable I-cpm decreases in most tissues with the 
largest decline occurring in uterus and mammary gland at one and two 
hours after injection. Mammary gland and uterus only have nine percent 
and 15 percent of the total label associated with the tissue that is TCA 
precipitable after two hours. 
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125 Figure 5. Tissue/blood of injected I. The tissue/blood ratio was 
calculated as the % dose of the total tissue associated cpra 
divided by the % dose of the total blood cpm. Tissue/blood 
ratios are shown for samples taken at 30 minutes, 1 and 2 
125 hours after injection of I-MRP in nonpregnant mice and mice 
at 11 days of gestation (n = 2-4 mice at each time). Key; L, 
liver; MG, mammary gland; U, uterus. 
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Figure 6. Percentage of TCA precipitable label associated with each 
tissue. The percentage of TCA precipitable label was deter-
125 
rained at 30 minutes, 1 and 2 hours after injection of I-
MRP. The percentage of TCA precipitable label is the TCA 
precipitable cpm associated with the tissue divided by the 
total cpm associated with the tissue*100. Values are the 
average and standard deviation of 3-5 mice at each time and 
normalized to the TCA precipitable label injected. Key: K, 
kidney; S, spleen; L, liver; MG, mammary gland; U, uterus. 
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To determine whether the greater decrease in TCA-insoluble MRP in 
the mammary gland and uterus was due to lysosomal degradation we treated 
125 pregnant mice with chloroquine for six days prior to I-MRP injection 
at 11 days of gestation. Chloroquine inhibits lysosomal proteolysis by 
accumulating in the lysosomes and increasing the intralysosomal pH. In 
chloroquine-treated mice there was an increase in the percentage of TCA 
precipitable label in mammary gland and uterus when compared with control 
mice two hours after injection (Table 4). The six-fold increase in 
mammary gland and three-fold increase in uterine content of acid-in­
soluble MRP compares with minor increases in other tissues. All tissues 
show less tissue-associated label, but this decrease is prominent in only 
mammary gland and liver which show a 4.4-fold and 2.3-fold decrease, 
respectively. 
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Table 4. Chloroquine treatment of pregnant mice 
% TCA precipitable cpm/mg tissue 
Control Chloroquine Control Chloroquine 
Tissue (n=3) (n=3) 
liver 66±6 60±8 28 .7+4 12 .6±1 
heart 56±6 66+13 21, .6+3 17, .5+1 
spleen 46+6 49+13 12. ,3+2 9, .6+1 
kidney 37+3 44+2 34. ,4+1 29, ,4+2 
mammary 
gland 8+0 46±2 33. 3±1 7. 6+1 
uterus 17±1 49±1 11. 9±1 10. 2±1 
NOTE. Mice at 6 days of gestation were treated daily until 11 days of 
gestation with 60 ug/g weight of chloroquine diphosphate or 
125 
sterile water. At 11 days I-MRP was injected into the heart 
and the mice were sacrificed after two hours. Tissues were 
dissected, weighed, counted, and TCA precipitation performed. The 
% TCA precipitable is the TCA precipitable cpm associated with 
each tissue divided by the total cpm associated with the 
tissue*100. The % TCA precipitable is normalized to the TCA 
precipitable cpm injected. The cpm/mg tissue is the total cpm 
associated with each tissue normalized to the wet weight of the 
tissue in mg. 
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DISCUSSION 
Synthesis of MRP occurs only in the placenta (2,3,6). The circulat­
ing level of MRP in maternal blood peaks at day 10 of gestation and 
declines to 30 percent of peak levels at day 13. Comparison of the rates 
of decline of MRP in the blood and of MRP mRNA in the placenta shows that 
the plasma protein declines more rapidly than the placental mRNA. This 
suggests that an event such as clearance, beyond those that regulate MRP 
mRNA levels, determines the rate of decline of MRP in the plasma. 
Clearance from the blood might involve rapid uptake by target tissues via 
a specific receptor or rapid removal for the purpose of clearing excess 
MRP from the bloodstream. 
The rate of clearance of MRP at all stages of gestation and in 
nonpregnant mice was much higher than the rate of clearance of serum 
albumin. Serum albumin has been shown to bind several tissues and this 
binding has been associated with distinct membrane proteins of 73, 56, 31 
and 18 kDa (13). Once bound, the albumin appears to be taken up by a 
endocytic mechanism (14). Maleylated albumin binds with high affinity to 
85, 35 and 15 kDa hepatic membrane proteins which have been partially 
purified under reducing conditions (15). From these results it seems 
that MRP is cleared by a different receptor than that which recognizes 
BSA. 
Recombinant glycosylated MRP possesses mannose-6-phosphate and binds 
to the mannose-6-phosphate receptor (7). Here, we have shown that MRP 
from placental extracts but not MRP in the blood contains raannose-6-
38 
phosphate. Also, short incubation of phosphorylated MRP with blood 
plasma results in the removal of the phosphate. Therefore, it seems the 
mannose-6-phosphate initially on MRP when it is in the placenta is soon 
removed after MRP is secreted. The function of the mannose-6-phosphate 
is probably to guide MRP during intracellular trafficking within the 
placental giant cells. Also, MRP binds specifically to 11-day uterine 
membrane preparations in the presence of excess mannose-6-phosphate 
(Nelson and Nilsen-Hamilton, manuscript in preparation). Thus, it 
appears that MRP uptake from the blood does not involve the mannose-6-
phosphate receptor. 
At day 11 of gestation we observed a biphasic clearance profile of 
MRP with half-lives of 36 minutes and 8.1 hours. These biphasic clear­
ance profiles are similar to the clearance profiles of placental lactogen 
in sheep (16) and rats (17,18) and of prolactin in rats (19), but MRP was 
cleared considerably slower than these other hormones. The 36-minute 
short half-life of MRP is longer than that found for other members of 
this hormone family. For example, the half-lives of placental lactogen 
in rats is 19.5 or 1.2 minutes, depending on the time in gestation (18), 
or 5.4 minutes (17). The half-life of prolactin is five minutes in 
euthyroid (19) and lactating rats (20,21). If MRP is cleared by the same 
receptor as these other proteins, then the receptor must have a lower 
affinity for MRP than for placental lactogen or prolactin. Alternately, 
MRP may be taken up by different receptors from the currently recognized 
lactogenic hormone receptors. We have evidence for a unique population 
of receptors for MRP that do not recognize other lactogenic hormones 
39 
(Nelson and Nilsen-Harailton, in preparation). The population of these 
MRP receptors may be much smaller than the population of lactogenic 
receptors. 
125 The temporal profile of I-MRP clearance was different at day 11 
than in nonpregnant mice and mice at the other times of gestation. At 
all other stages tested (nonpregnant, days 6 and 15) tracer MRP was 
slowly released into the bloodstream for the first several hours after 
injection. The most likely explanation for this result is that the heart 
contains saturable binding sites for MRP. The slow release is proposed 
not to be a significant factor at day 11 because the MRP binding sites 
are expected to be saturated by endogenous MRP which is present in the 
bloodstream at a concentration of about 7.5 /ig/ml. Therefore, less of 
the injected tracer is likely to be trapped in the heart at 11 days of 
gestation. Because of this slow release of MRP by the heart at all other 
stages of development, we were only able to measure the short half-life 
of MRP in 11 day pregnant mice. In vitro studies with plasma from 11 day 
pregnant and nonpregnant mice showed MRP is not significantly degraded by 
plasma components and that the clearance rates we have measured can be 
attributed to clearance of intact MRP from the blood. 
We found no consistent significant differences in the association of 
MRP with different tissues that would indicate a selective accumulation. 
But we did find that MRP tended to distribute into the tissues more than 
BSA. This was evident from the much higher tissue/blood ratios for MRP 
than BSA. The differences in tissue/blood ratios for MRP vs. BSA varied 
from four-fold in mammary gland to 13-fold in spleen. 
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The mammary gland and the uterus rapidly take up radioiodinated MRP 
immediately after it appears in the bloodstream. Simultaneously with 
this uptake is a large decrease in the percentage of radiolabel that is 
TCA precipitable in these tissues compared with the radiolabel in the 
blood. At 11 days of gestation, this large decline in the percentage of 
TCA precipitable label occurs in the uterus and mammary gland between 30 
125 
minutes and two hours after injection of I-MRP. Coincident with this 
decline in acid-insoluble radiolabel is a very large increase in the 
tissue/blood ratio of label in each tissue. This suggests that these 
tissues take up and degrade MRP. 
To determine whether the uptake and degradation of MRP by the uterus 
and mammary gland might involve receptor-mediated endocytosis, we tested 
the effect of chloroquine, an inhibitor of lysosomal degradation on 
accumulation of TCA-insoluble MRP in the tissues. When mice were treated 
with chloroquine prior to injection of MRP there was a selective increase 
in the percentage of TCA precipitable label in mammary gland and uterus 
125 two hours after I-MRP injection when compared with control mice. This 
suggests that receptor-mediated endocytosis and subsequent degradation of 
MRP probably occurs in these tissues. The observation that chloroquine 
treatment had little effect on the percent of acid-precipitable MRP in 
the other tissues tested suggests these tissues do not actively degrade 
MRP by a similar lysosome-mediated mechanism. A characteristic of a 
number of hormones and growth factors is degradation after receptor-
mediated endocytosis. Thus, these results suggest the mammary gland and 
the uterus are MRP target tissues. 
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The temporal profile of its secretion by the placenta and its 
homology with prolactin and growth hormone indicates MRP may be a hormone 
involved in fetal development. We have shown that MRP is rapidly cleared 
from the bloodstream and that the rate of clearance is likely to be 
faster than the rate of its synthesis and secretion by the placenta. 
The rapid clearance of MRP observed in mid-gestation may be mediated 
by a specific receptor. Although all tissues analyzed took up MRP, 
mammary gland and uterus were different because they also rapidly 
degraded the protein. The early increase in accumulation of MRP-
associated radiolabel in the mammary gland and uterus correlates well 
with the short half-life of MRP measured in the blood at mid-gestation. 
From the evidence we have presented, we proposed MRP is rapidly cleared 
from the blood via specific receptors on the mammary gland and uterus. 
The protein is then proposed to be endocytosed and degraded. It is 
expected that MRP delivers a signal to some cells in these tissues. We 
are currently conducting receptor binding and crosslinking studies to 
show the existence of a specific MRP receptor. 
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ABSTRACT 
Mitogen regulated protein (MRP; also called proliferin) is a 
proposed new placental hormone of the prolactin-growth hormone family 
involved in fetal development. MRP is taken up and degraded by the 
uterus and mammary gland at mid-gestation in the mouse and this uptake 
correlates with its temporal profile of synthesis and secretion. To 
determine if the uterus is a target tissue for MRP, we tested uterine 
membrane preparations at mid-gestation for MRP binding. We found peak 
binding activity at 11 days of gestation. Scatchard analysis of 11 day 
uterine membranes showed a = 3.5*10 M and B^^^ = 72 fmoles/mg 
membrane protein. The proposed receptor on uterine membranes showed a 
single affinity for MRP and prolactin or mannose-6-phosphate did not 
compete for binding. Chemical crosslinking of the receptor-MRP complex 
with disuccinimidyl suberate and SDS-PAGE analysis under reducing 
conditions revealed a 57 kDa complex which results in a receptor M^ = 23 
kDa. We propose that MRP is a new placental hormone which exhibits 
functional effects on the uterus for the purpose of coordinating fetal 
development and maternal preparation for birth. 
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INTRODUCTION 
Mitogen Regulated Protein (MRP) is a 34 kDa glycoprotein secreted by 
Swiss 3T3 cells after stimulation by growth factors (1). It is a member 
of the prolactin-growth hormone family of proteins and has also been 
called proliferin (2,3). MRP is synthesized in murine placenta and 
secreted into the maternal bloodstream during gestation (4-7). The 
temporal profile of the placental mRNA content and maternal MRP blood 
concentrations over gestation and its similarity in sequence to prolactin 
show that MRP is a developmentally regulated protein with a possible 
hormonal function (7). Studies of the rates of its in vivo clearance 
using radioiodinated MRP show MRP to be cleared from the maternal 
bloodstream most efficiently at mid-gestation and utilized most effi­
ciently by mammary gland and uterus (Nelson et al., in preparation). 
This suggests there is a receptor that binds and takes up MRP on these 
tissues. 
The receptors that could bind MRP include the mannose-6-phosphate 
and asialoglycoprotein receptors. However, MRP found in the blood is 
sialyated (Y. Fang, unpublished results) and does not contain mannose-6-
phosphate (Nelson et ai., in preparation). This suggests that these 
receptors do not bind MRP in vivo. To determine if there is a MRP-
specific receptor, we tested uterine membrane preparations at mid-
gestation for their ability to bind MRP. Our results show uterine 
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membranes contain a specific receptor that is developmentally regulated. 
This provides additional evidence that MRP is a hormone involved in fetal 
development. 
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MATERIALS AND METHODS 
Materials 
MRP was purified in our laboratory from conditioned medium of a 
125 Swiss 3T3 cell line stimulated by phorbol myristate acetate. Na I was 
purchased from Amersham. Enzymobeads and desalting columns (10-DG) were 
purchased from Bio-Rad. Glucose was purchased from Fisher. BSA (Cohn 
fraction V) and mannose-6-phosphate were purchased from Sigma. Disuc-
cinimidyl substrate was purchased from Pierce. Prolactin was a generous 
gift of Dr. A. F. Parlow. All other chemicals used were reagent grade or 
more pure. 
Methods 
Membrane preparation 
The procedure for membrane preparation is a modification of Shiu et 
al. (8). Uterine tissue was dissected from pregnant mice at 11 days of 
gestation and washed in 0.3 M sucrose. All subsequent steps are com­
pleted at 4°C. The tissue was minced into small pieces and ice-cold 0.3 
M sucrose was added to 10 ml/g tissue. The suspension was homogenized 
for four minutes at a medium setting in the Tekmar Tissuemizer followed 
by a one-minute homogenization at the highest setting. The homogenate 
was centrifuged at 1500 g for 20 minutes and the pellet was discarded. 
The supernatant was centrifuged at 15,000 g for 20 minutes and the pellet 
was discarded. The resultant supernatant was centrifuged at 100,000 g 
for 90 minutes. The pellet was resuspended in 250 mm tris, 10 mm MgClg, 
pH 7.6 and stored in aliquots at -70°C until ready for use. 
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Radioiodination 
MRP was radiolodlnated using immobilized glucose oxidase and 
lactoperoxidase (Enzymobeads, Bio-Rad Company). Two to three micrograms 
per milliliter of MRP was incubated with 50 pi of washed Enzymobeads, 6.5 
125 
mCi/ml of Na I, and 323 pg/ml of a-D-glucose in 65 mM phosphate 
buffer, pH 7.2 for 25 minutes at 22°C in a total volume of 155 fil. Fifty 
millimolar phosphate buffer, pH 7.4 was added to the reaction mixture to 
a final volume of one milliliter. The mixture was microfuged for 5 
minutes at 4oC and the supernatant was loaded onto a Bio-Rad 10 DG column 
previously washed with one percent BSA in 50 mM phosphate buffer, pH 7.4 
and eluted with 50 mM phosphate buffer, pH 7.4. One milliliter fractions 
containing 100 /il of one percent BSA were collected. Fractions 4, 5 and 
6 were pooled, loaded onto a second desalting column, and one milliliter 
fractions were again collected. Analysis of each fraction by trichloro­
acetic acid (TCA) precipitation and sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) was then completed. Fractions containing 
greater than 75 percent TCA precipitable protein were used for experi­
ments . 
TCA precipitation 
Silica gel impregnated glass fiber strips (4.8 cm x 1 cm) were 
spotted 1 cm from the bottom with an equal volume of two percent potas­
sium iodide and radioiodinated MRP and developed in 30% (v/v) methanol, 
10% (v/v) glacial acetic acid and 10% (v/v) trichloroacetic acid. The 
developed strips were air-dried, cut in half to separate acid soluble and 
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insoluble material, and counted in a Tracor Analytic Gamma Trac 1191 
gamma counter. The acid insoluble counts remaining at the origin were 
divided by the total counts spotted to obtain the TCA precipitable 
protein fraction. 
SDS-PAGE 
SDS-PAGE was completed according to Ornstein (9) and Davis (10) as 
modified by Nilsen-Hamilton and Hamilton (11). The resolving gel 
consisted of a 7.5-15 percent linear polyacrylamide gradient and the 
stacking gel was five percent polyacrylamide. Electrophoresis was 
completed at 12.5 mamps for 4.5-5 hours at 22°C. 
Receptor binding assay 
Binding assays were modified as described (8) by including 1-10 mM 
mannose-6-phosphate in the assay mixture. Briefly, 0.5-1.0 mg/ml uterine 
membrane protein was incubated in 250 mM Tris, 10 mM MgClg, pH 7.6 
containing one percent BSA, 1-10 mM mannose-6-phosphate, 0.1 mM PMSF and 
0.1-1.0 ng/ml I-MRP for 90 minutes at 24°C. Nonspecific binding was 
determined by the addition of 100-fold excess unlabeled MRP to the above 
reaction mixture and was subtracted from total binding to obtain the 
125 
specific binding of I-MRP. One milliliter of ice cold 250 mM Tris, 10 
mM MgClg, pH 7.6 buffer was then added and the mixture was immediately 
filtered under vacuum using either a mixed ester membrane (Millipore RAWP 
02500, 1.2 nm pore size) or Durapore membrane (Millipore GVWP 02500, 0.2 
125 fim) to separate free and bound I-MRP. The filter was washed six times 
with 3 ml of ice cold buffer and counted in a Tracer Analytic Gamma Trac 
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1191 gamma counter. 
Chemical crosslinking 
125 Uterine membranes were incubated with I-MRP in the presence or 
absence of excess unlabeled MRP or unlabelled prolactin. After incuba­
tion, disuccinimidyl suberate was added to the mixture to 0.2 mM and 
incubated at 4°C for 20 minutes. An equal volume of ice cold 250 mM 
tris, 10 mM MgClg, pH 7.6 was added and the mixture was microfuged at 4°C 
for 10 minutes. The pellet was washed one time with ice cold buffer and 
microfuged. The washed pellet was suspended in electrophoresis buffer 
and analyzed by SDS-PAGE and autoradiography. 
Protein determination 
Protein concentrations were determined using the Coomassie blue G-
250 Protein Assay Reagent from Pierce Chemical Co. The assay is based on 
the Bradford method (12) and bovine serum albumin was used as the 
standard. 
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RESULTS 
Receptor Binding at Mid-gestation 
We conducted receptor binding assays on uterine and mammary gland 
membrane preparations from day 10-14 (Figure 1). To eliminate any 
potential binding contribution to the mannose-6-phosphate receptor, we 
determined that mannose-6-phosphate in concentrations of 1 mM completely 
blocked binding to the presumed mannose-6-phosphate receptor and included 
1 mM mannose-6-phosphate in the reaction mixtures. For uterine membranes 
there was a peak of receptor binding at day 11 of gestation with a rapid 
decline between day 11 and 12 of gestation. Almost no binding activity 
was found in day 14 uterus. Mammary gland membrane preparations showed 
greatest binding at day 10 and with little or no binding after day 11 of 
gestation. However, we experienced problems with filtering mammary gland 
125 
membrane preparations to separate bound and unbound I-MRP. The 
mammary gland mixtures generally filtered more slowly than uterine 
membrane mixtures and it was difficult to wash the filters as exten­
sively. For this reason, we used uterine membrane preparations for 
subsequent studies. 
Receptor Characterization 
We used uterine membrane preparations from 11 days of gestation to 
characterize the MRP receptor. The binding isotherm (Figure 2a) shows 
saturable kinetics with half maximal binding at 1.28 x 10 M. The 
Scatchard plot (13) shows a single affinity receptor population with an 
- 1 0  
average Kp = 3.5 x 10 M and maximal binding of 72 fmoles/mg membrane 
55 
4 
day of gestation 
Figure 1. Receptor binding of MRP. Receptor binding was measured in 
membrane preparations from uterus (•) or mammary gland (H) 
isolated from mice at day 10 through day 14 of gestation as 
described in Materials and Methods. Specific binding was 
measured by subtracting the cpm bound in the presence of a 
100-fold excess of unlabeled MRP. Values are the average and 
standard deviation of 2 (day 10, 13, 14), 3 (day 13), and 4 
(day 11) different membrane preparations. 
Figure 2. Concentration dependence of MRP binding, a) Membranes 
prepared from uterine tissue at 11 days of gestation were 
125 incubated with increasing concentrations of I-MRP in a 
total volume of 250 /il as described in Materials and Methods. 
Specific binding was determined in the presence of excess 
125 
unlabeled MRP at each concentration of I-MRP for duplicate 
samples. Half-maximal binding was found at 1.28 x 10 M. 
b) Scatchard plot of MRP binding with membranes prepared from 
1 1  d a y s  o f  g e s t a t i o n .  =  3 . 5  x  1 0  M  a n d  = 7 2  
fmole/mg protein. 
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protein (Figure 2b). Nonspecific binding with 11 day uterine membranes 
represented about 7% of the total TCA precipitable label in these assays. 
Receptor binding is linear up to about 0.8 mg/ral of membrane protein with 
uterine membranes from 11 days of gestation (Figure 3). 
Receptor association is rapid and shows association kinetics 
indicative of a second order bimolecular process (Figure 4). Using the 
linear portion of the association curve and the equation for a second 
order process, k^ = In [B(A-x)/A(B-x)]/t(A-B), where A, B, and x are the 
ligand, receptor, and receptor-ligand concentrations, we calculated an 
association rate constant of 1.35 x 10^ M ^ sec ^. The receptor concen­
tration was obtained from the B of the Scatchard analysis and it was 
max •' 
assumed there was only one binding site per receptor molecule. 
The receptor shows reversible binding kinetics indicative of a first 
order dissociation process with half maximal dissociation after 12 
minutes (Figure 5). The calculated first order dissociation rate 
-4 -1 
constant, k is 4.18 x 10 sec . MRP binding reaches equilibrium 
after 30 minutes. The calculated from the association and dissocia­
tion rate constants is 3.1 x 10 M using the formula = k ^ /k^. 
Optimal binding of MRP occurred at pH 7.6 (Figure 6) with a signifi­
cant decline in binding around the pH optimum. There was no binding at 
very acidic (pH 4.4) or basic (pH 8.3) conditions. 
Prolactin did not compete for binding with MRP at a concentration up 
to 45 nM (Figure 7). 
We used the chemical crosslinker, disuccinimidyl suberate, to 
crosslink MRP with its receptor (Figure 8). The autoradiogram shows a 
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Figure 3. Receptor binding activity as a function of membrane concentra­
tion. Receptor binding was measured with increasing concen­
trations of uterine membranes prepared from 11 days of 
gestation. Specific binding was determined in the presence of 
excess unlabeled MRP for duplicate samples. Average specific 
binding: 2.69 ± 0.27 fraole/mg membrane protein. 
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Figure 4. Receptor association with time. Uterine membranes prepared 
125 from mice at 11 days of gestation were incubated with I-
MRP in the absence or presence of excess unlabeled MRP as 
described in Materials and Methods. Duplicate samples were 
taken at various times of incubation and the specific binding 
determined. The rate of association, k^^ = 1.35 x 10^ ± 2.5 x 
5 -1 -1 10 M sec was calculated using the six points in the 
linear range and the second order rate equation, k^ = In 
[B(A-x)/A(b-x)]/t(A-b). 
61 
4 
2 
1 
O) 
O 
30 40 O 10 20 50 60 70 
Time (minutes) 
Figure 5. MRP dissociation from the receptor with time. Uterine 
membranes prepared from mice at 11 days of gestation were 
incubated with ^^^I-MRP for 60 minutes in the absence or 
presence of excess unlabeled MRP in a total volume of 250 ffl 
as described in Materials and Methods. Excess unlabeled MRP 
was then added and the incubation continued. Specific binding 
for duplicate samples was determined at the indicated times. 
Specific binding at 0 minutes was determined without the 
addition of unlabeled MRP. The plot is a logarithmic trans­
formation of the data, k ^ =4.18 x 10 sec calculated by 
the method of least squares. 
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4.4 6.6 7.2S 7.2T 7.6 8.3 
pH 
Figure 6. Receptor binding as a function of pH. Specific binding to 11 
day uterine membranes was determined at pH 4.4, 6.6, 7.2, 7.6, 
and 8.3. The pH dependency was tested using the following 
buffers: 250 mM Tris, 10 mM MgClg pH 8.3; 250 mM Tris, 10 mM 
MgClg pH 7.6; 250 mM Tris, 10 mM MgClg pH 7.2 (pH 7.2T); 200 
mM sodium phosphate, 10 mM MgClg pH 7.2 (pH 7.2S); 250 mM 
sodium citrate, 10 mM MgClg pH 6.6; 250 mM sodium acetate, 10 
mM MgClg pH 4.4. 
63 
200 
O) 
c 
•o 
c 
160 
120 
O 
0 22 66 44 88 110 
ng/ml protein 
Figure 7. Receptor binding in the presence of prolactin. MRP binding to 
11 day uterine membranes was determined in the presence of 
increasing concentrations of unlabeled MRP (•) or prolactin 
(A) as described in Materials and Methods. 
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Figure 8. Identification of MRP-binding protein by crosslinking. 
Receptor binding was performed as described in Materials and 
Methods in the absence or presence of excess unlabeled 
prolactin or MRP. Disuccinimidyl suberate was added and 
incubated for 20 minutes in electrophoresis buffer. SDS-PAGE 
was completed under reducing conditions. Lane 1, no unlabeled 
MRP; Lane 2, + unlabeled prolactin; Lane 3, + unlabeled MRP. 
Arrow points to the position of 57 kDa receptor-MRP complex. 
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distinct band at 57 kDa that is diminished in the presence of excess 
unlabeled MRP but not in the presence of prolactin. We also performed 
125 the crosslinking of I-MRP in the absence of uterine membranes and 
found no 57kDa band. Using a Mr of 34 kDa for MPR, the receptor or 
binding unit for MRP is about 23 kDa. 
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DISCUSSION 
MRP binds to the cation-independent mannose-6-phosphate receptor in 
liver and placental membranes with maximal binding occurring at late 
gestation (14). Most of the cation-independent mannose-6-phosphate 
receptor is located intracellularly (15) and serves to target polypep­
tides to the lysosomes. Although there is evidence that ligand binding 
to the plasma membrane cation-independent mannose-6-phosphate receptor 
activates phospholipase C and that MRP is one of those ligands (16), we 
doubt that this receptor is involved in transducing a signal from MRP in 
vivo because circulating MRP does not contain mannose-6-phosphate (Nelson 
et al., in preparation). 
Our recent findings showed that radioiodinated MRP is rapidly 
degraded by mammary gland and uterine tissue in a chloroquine-sensitive 
manner (Nelson et al., in preparation). Based on these findings, we 
collected membranes from mammary gland and uterus in mid-gestation. We 
found peak binding activity for mammary gland and uterine membranes 
prepared from mice at days 10 and 11 of gestation, respectively. Studies 
in our laboratory with placental homogenates also showed specific MRP 
binding. MRP binding in the placenta peaked on day 12 (data not shown). 
Two of these three tissues (mammary gland and uterus) were tissues 
identified by in vivo clearance studies as those likely to express a 
receptor for MRP (Nelson et al., in preparation). We elected to use 11-
day uterine membranes for receptor characterization because separation of 
unbound from bound label in mammary gland incubations was a slower 
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process. 
The developmental profile of expression of the MRP receptor paral­
lels that of MRP (17). However, the circulating level of MRP at mid-
gestation is extremely high (4-20 /xg/ml at peak levels) and declines with 
an apparent half-life of 33 hours. Thus, a high affinity receptor such 
as we have identified would be capable of being stimulated by MRP 
throughout much of development. The developmentally-regulated expression 
of this receptor suggests that the ability of MRP to initiate an intra­
cellular signal in the uterine cells is determined by the presence of the 
receptor rather than its ligand. 
After day 11 of gestation, the MRP concentration in the blood 
declines at a constant rate with a half-life of 33 hours. Over the same 
period the level of MRP mRNA in the placenta decreases with a half-life 
of 48 hours. Therefore, it seems that MRP is rapidly removed from the 
blood. Uterine and mammary gland receptors are unlikely to be involved 
in this clearance because their gestational profile of expression is not 
coincident with the period of decline. This suggests that, as well as 
the uterine and mammary gland receptors, there is another receptor for 
MRP involved in its clearance. 
Other prolactin-like proteins are synthesized and secreted by rodent 
placentae during gestation (18-23). Two of these, placental lactogens I 
and II, have receptors that have been characterized (24-28). The MRP 
receptor is similar to these receptors in that binding activity changes 
over gestation. At 11 days of gestation, receptors on the uterine 
membranes have an average = 3.5 x 10 M and show maximal MRP binding 
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of 72 fmoles/mg membrane protein. At day 10 of gestation the was 6.5 
X 10 and maximal MRP binding was 130 fmoles/mg protein, 
respectively, while we could not measure the at day 13 due to low 
specific binding. There was no significant difference between receptor 
affinities measured at days 10 and 11 of gestation. 
The MRP receptor displays a single affinity for its ligand. This 
indicates the uterus contains a single population of active receptors. 
Unlike placental lactogen receptors (24,26,27) prolactin does not compete 
for binding to the MRP receptor at concentrations up to 45 nM. These 
data indicate the MRP receptor is not the same as the placental lactogen 
I receptor for which placental lactogen I binding is effectively competed 
for by prolactin. 
The MRP receptor has a sharp pH-optimum for binding MRP. We specu­
late the decreased binding at low pH may be part of a mechanism employed 
to separate MRP from its receptor during internationalization. This 
model has been proposed for receptor-ligand complexes that are endo-
cytosed. Our previous results suggest the uterus and mammary gland 
degrade MRP by a lysosomal-mediated mechanism which is common for ligands 
that are taken up by receptor-mediated endocytosis (Nelson et ai., in 
preparation). 
The uterine MRP receptor shows rapid association kinetics with an 
association rate constant, k^, of 1.35 x lO^M ^ sec ^ assuming second 
order rate kinetics. MRP binding is reversible and occurs at a dissocia-
-4 -1 tion rate constant of 4.18 x 10 sec , assuming first order kinetics 
apply. The calculated dissociation constant from these data is 3.1 x 
69 
M, which matches well with the = 3.5 x 10 M calculated from 
the Scatchard plot. 
The molecular weight of the receptor-MRP complex which could be 
identified by crosslinking was 57 kDa under reducing conditions. The 
calculated for the receptor is thus 23 kDa after subtracting 34 kDa as 
representative of the of MRP. Small molecular weight "receptors" have 
also been found for the placental lactogens. For example, the fetal 
sheep liver placental lactogen receptor was identified as M^ of 38 kDa 
(29), the receptor in murine ovaries and liver was 42 and 50 kDa (24), 
and the murine liver receptor was 45 kDa (27). Proteins of 28-93 kDa 
have been identified as prolactin binding lactogen receptors in a number 
of tissues in rats, rabbits, and pigs (30-38). Thus, the MRP receptor is 
substantially different from the receptor that binds the placental 
lactogens at mid- and late-gestation. However, the M^ of the MRP 
receptor is similar to the prolactin binding lactogen receptors found in 
rat kidney (34) and rabbit mammary gland (36). The receptor to which MRP 
binds is not likely to be the lactogenic receptor because MRP binding is 
not competed for by prolactin. 
In summary, we have characterized a high-affinity receptor for MRP 
from murine uterine membrane preparations. Receptor binding peaks at 11 
days of gestation and the affinity for MRP differs at different days of 
gestation. Prolactin does not compete for binding. Based on its 
specificity and molecular weight, we conclude the receptor is not related 
to previously identified prolactin or placental lactogen receptors. This 
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finding supports the hypothesis that MRP is a new, placentally-derived, 
and developmentally-regulated hormone with a different function from 
prolactin and the placental lactogens. 
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SUMMARY 
Nilsen-Harailton (41) proposed a model for the role of MRP during 
mammalian development. She proposed that transforming growth factor a 
(TGF-a) is released from the decidual cells of the developing placenta 
and then stimulates placental giant cells to secrete MRP. This MRP then 
binds to nearby fetal cells and is also secreted into the maternal blood 
where it binds to a target tissue. The result of the endocrine action is 
to stimulate the release of insulin-like growth factor which then acts in 
an autocrine factor to stimulate proliferation. It is this proliferation 
that initiates the next phase in a coordinated development process. The 
focus of my research was to identify the MRP target tissue and to charac­
terize a specific MRP receptor on that tissue. MRP synthesis occurs in 
the placenta and reaches maximum levels during mid-gestation. The 
temporal profile of MRP synthesis correlates with the maternal blood 
concentration during gestation. I've determined that tracer radioiodin-
ated MRP is cleared from the maternal blood circulation rapidly at mid-
gestation. Furthermore, I have identified two tissues that rapidly take 
up and degrade MRP. 
The binding of a ligand to a receptor at the cell surface may 
involve internalization of the ligand with subsequent transfer to the 
Golgi and lysosomes (42). Epidermal growth factor (EGF) binds its 
receptor and is transported to the lysosome for degradation (43). 
Prolactin is a hormone internalized and found associated with the 
lysosomes (44). Human growth hormone is transported to the lysosomes in 
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human lymphocyte cultures and lysosomotropic agents such as NH^Cl and 
chloroquine inhibit degradation of growth hormone (45). My results show 
decreased degradation of radioiodinated MRP in uterus and mammary gland 
after treatment of pregnant mice with chloroquine. This suggests that 
MRP is degraded in the lysosomes and may follow a similar internalization 
pathway as EGF, growth hormone, prolactin, and other ligands such as 
insulin (46) and low density lipoproteins (47). 
Preparations of murine uterine membranes from mid-gestation show 
receptor binding activity to radioiodinated MRP. Binding peaks on day 11 
and declines over the next few days of gestation. The average at 11 
days of gestation obtained by Scatchard analysis was 3.5 x 10 M. This 
compares favorably with the calculated from the kinetic studies of 3.2 
X 10 M. The average was 72 fmole/mg protein. These binding 
-10 
characteristics at 11 days of gestation compare with a = 6.5 x 10 M 
and = 130 fmole/mg protein at day 10 of gestation. I could not 
determine the or B^^^ at day 13 due to low specific binding. The 
difference in receptor affinities and maximal binding was not significant 
between days 10 and 11. The placental lactogens exhibit different 
binding affinities and maximal binding dependent on the day of gestation 
(48), but this change occurred over a four-day period. The amount of MRP 
binding decreases significantly (p<.005) between days 11 and 14 of 
gestation and this change may reflect a requirement for MRP at a specific 
time of gestation. 
I have demonstrated that the MRP receptor is specific for MRP. 
Prolactin at concentrations up to 45 nM does not compete for binding with 
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MRP on uterine membrane preparations. Mannose-6-phosphate does not block 
MRP binding at concentrations up to 10 mM. Thus, MRP does not bind to 
the mannose-6-phosphate receptor at this stage of gestation. Prolactin 
competes with placental lactogens for binding to placental lactogen 
receptors (48-50). Recombinant MRP does not bind to the prolactin 
receptor (16) or to Nb^ lymphoma cells (K. Ebner, personal communica­
tion), a cell line known to bind lactogenic hormones. This evidence 
supports the existence of a specific MRP receptor that is not related to 
the placental lactogen receptor. 
MRP does not bind to its receptor under acidic conditions. This is 
in agreement with the mannose-6-phosphate and other receptors that 
transport ligands to intracellular compartments which also release their 
ligands at acidic pH conditions (30,51). This is an interesting finding 
if the MRP-receptor complex follows an internalization process similar to 
other internalized hormones. The change in pH that occurs in the 
endocytotic vesicles could allow dissociation of the receptor-MRP complex 
with subsequent MRP degradation in the lysosomes. The fact that in vivo 
degradation declines upon treatment with the lysosomotropic agent, 
chloroquine, suggests that MRP may be degraded in the lysosomes. 
However, the receptor may not be recycled because receptor numbers 
decrease with advancing gestation. This suggests the receptor may also 
be degraded upon internalization. 
The molecular weight of the receptor of 23 kDa is small when 
compared with receptors of prolactin and the placental lactogens. 
However, several groups identified prolactin binding subunits of 28-40 
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kDa (52-56) and the 23 kDa species may be a subunit of the receptor. 
Placental lactogen receptors have a range of molecular weights depending 
on the tissue examined of 38 kDa - 50 kDa (48,50,57). The difference in 
receptor molecular weight between MRP and placental lactogens also 
supports the hypothesis of a specific MRP receptor. 
I conclude that MRP has a specific receptor that appears in uterine 
tissue at mid-gestation. The presence of this receptor along with the 
placental location of its synthesis, its temporal profile of MRP secre­
tion into the maternal bloodstream, and the homology of MRP to prolactin 
supports MRP being a placental hormone involved in fetal development. 
Other prolactin-like hormones, the placental lactogens, possess lacto­
genic activity (17,58). The biological role of MRP is not known, but the 
relationship to prolactin and its binding to both uterine and mammary 
gland tissue indicate these are target tissues. 
Faria et al. (21) speculated that placental lactogens may also play 
a role in growth and differentiation of the uterine decidua and in fetal 
growth. This role reflects a somatotropic effect similar to growth 
hormone, another hormone of the prolactin-growth hormone family (59). 
The biological action of MRP on uterine tissue, specifically, may be to 
stimulate uterine growth and this action may be mediated through the 
insulin-like growth factors as proposed by Nilsen-Hamilton. 
The discovery of an MRP receptor in uterus and mammary gland leads 
to much future research relating to further receptor characterization, 
biological function during gestation, and how the MRP binding signal is 
transduced. 
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Purification of the MRP receptor can lead to a better understanding 
of receptor function by characterizing binding, transmembrane, and signal 
domains. One may also propose a catalytic function, if it exists. The 
identification and expression of a cDNA for the receptor will assist in 
primary sequence identification and will allow comparison with other 
receptor proteins to determine similarity of functional domains. 
Prolactin and the placental lactogens promote lactogenic activity 
and MRP may also stimulate a lactogenic response. One can assay for 
lactogenic activity in mammary epithelial cell cultures (49) and it will 
be useful to test MRP for this activity. I have suggested MRP may 
stimulate somatotropic effects on uterine tissue. One can determine 
potential somatotropic function by competition assays with growth hormone 
for somatotropic binding sites on IM-9 lymphocytes (54). Furthermore, it 
will be useful to establish the relationship between MRP binding and IGF 
stimulation, if one exists. Growth of uterine cells in primary culture 
and assay of MRP binding and IGF induction may provide evidence of such a 
relationship. 
Primary cell culture would also be useful in the study of signal 
transduction mechanisms utilized after MRP-receptor binding, although an 
immortal cell line that contains the MRP receptor would be even more 
useful. 
This future research will provide additional evidence that MRP is a 
placental hormone with a defined biological role during gestation and 
help to elucidate the molecular mechanism of its action. 
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